Suehiro T, Yamamoto M, Yoshida K, Ohno F
Second Department of Internal Medicine, Kochi Medical School, Japan.
Clin Chem. 1993 Jan;39(1):60-5.
We determine the concentration of proapolipoprotein (proapo) A-I and its ratio with total apolipoprotein (apo) A-I (proapo A-I/total apo A-I) in plasma of patients with liver disease; we used a noncompetitive sandwich method, an enzyme-linked immunosorbent assay. The mean (SD) proapo A-I concentrations in patients with decompensated or compensated liver cirrhosis were higher than in normal subjects: 88 (25), 105 (36), and 69 (25) mg/L, respectively. The mean (SD) ratio (expressed as %) for each of these types of liver cirrhosis was also higher than in normal subjects: 10.0 (3.5), 10.2 (3.9), and 4.6 (1.6), respectively. In the patients, the proapo A-I concentration was positively correlated with the concentration of high-density lipoprotein subtype 2 cholesterol (HDL2-C) (r = 0.736), and the proapo A-I/total apo A-I ratio was correlated inversely with the HDL3-C concentration (r = -0.609). The activity of proapo A-I converting enzyme in patients with liver cirrhosis (62 +/- 30 nmol/h per liter) was significantly (P < 0.01) lower than that in normal subjects (172 +/- 55 nmol/h per liter). The increases of the plasma proapo A-I concentration and ratio in patients with liver cirrhosis may be caused by a decreased production of the converting enzyme in the liver. The increase of plasma proapo A-I may thus also affect the circulating HDL subtypes.
我们测定了肝病患者血浆中前载脂蛋白（proapo）A-I的浓度及其与总载脂蛋白（apo）A-I的比值（proapo A-I/总apo A-I）；我们采用了一种非竞争性夹心方法，即酶联免疫吸附测定法。失代偿期或代偿期肝硬化患者的平均（标准差）proapo A-I浓度高于正常受试者，分别为88（25）、105（36）和69（25）mg/L。这些类型的肝硬化患者各自的平均（标准差）比值（以%表示）也高于正常受试者，分别为10.0（3.5）、10.2（3.9）和4.6（1.6）。在患者中，proapo A-I浓度与高密度脂蛋白2型胆固醇（HDL2-C）浓度呈正相关（r = 0.736），而proapo A-I/总apo A-I比值与HDL3-C浓度呈负相关（r = -0.609）。肝硬化患者中proapo A-I转换酶的活性（62±30 nmol/h每升）显著低于正常受试者（172±55 nmol/h每升）（P < 0.01）。肝硬化患者血浆proapo A-I浓度和比值的升高可能是由于肝脏中转换酶产生减少所致。因此，血浆proapo A-I的升高也可能影响循环中的HDL亚型。
